Incannex Healthcare Inc
IXHL0.152USD
-0.458-75.10%
Close 04/29, 16:00（ET）Quotes delayed by 15 min
2.70MMarket Cap
LossP/E TTM
More Details of Incannex Healthcare Inc Company
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Company Info
Company codeIXHL
Company nameIncannex Healthcare Inc
IPO dateMar 18, 2022
Founded at2023
CEOMr. Joel Latham
Number of employees9
Security typeOrdinary Share
Fiscal year-endMar 18
Address18 East 50th Street
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10022
Phone
Website
Company codeIXHL
IPO dateMar 18, 2022
Founded at2023
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
--
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
--
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
169.20K
+146.20%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
--
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
--
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
169.20K
+146.20%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
Australia
74.00K
0.00%
By Business
By Region
No Data
Shareholder
Update time: Tue, Apr 8
Update time: Tue, Apr 8
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
5.73%
Valentine (Troy Robert)
3.76%
Anastassov (George)
2.79%
Other
73.71%
Shareholder Statistics
Shareholder
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
5.73%
Valentine (Troy Robert)
3.76%
Anastassov (George)
2.79%
Other
73.71%
Type
Shareholder
Proportion
Individual Investor
16.57%
Corporation
14.01%
Investment Advisor
0.82%
Research Firm
0.37%
Investment Advisor/Hedge Fund
0.07%
Other
68.18%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
36
9.08M
33.58%
+3.85M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
2023Q1
10
20.53K
0.03%
-60.83K
2022Q4
10
50.18K
0.08%
-3.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
L1 Capital Global Opportunities Master Fund Ltd.
1.93M
7%
+1.93M
--
Mar 10, 2025
S.H.N. Financial Investments Ltd
1.93M
7%
+1.93M
--
Mar 10, 2025
Latham (Joel)
1.58M
5.73%
--
--
Oct 21, 2024
Valentine (Troy Robert)
1.04M
3.76%
--
--
Oct 21, 2024
Anastassov (George)
769.72K
2.79%
--
--
Oct 21, 2024
Changoer Lekhram
639.55K
2.32%
--
--
Oct 21, 2024
Widdows (Peter)
270.85K
0.98%
--
--
Oct 21, 2024
Swan (Joseph)
169.20K
0.61%
+100.48K
+146.20%
Oct 23, 2024
AdvisorShares Investments, LLC
165.50K
0.6%
+38.51K
+30.32%
Dec 31, 2024
Clark (Robert)
100.00K
0.36%
--
--
Oct 21, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
AdvisorShares Psychedelics ETF
4.37%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Proportion4.37%
Amplify Alternative Harvest ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data